Clinical trial
Safety and Efficacy Study of Ruxolitinib in the Treatment of Severe Acute Respiratory Syndrome Due to SARS-COV-2
NCT04414098 is registered in ClinicalTrials.gov with Marcelo Iastrebner as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy Study of Ruxolitinib in the Treatment of Severe Acute Respiratory Syndrome Due to SARS-COV-2
- Lead sponsor
- Marcelo Iastrebner
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 1, 2020
- Completion date
- September 15, 2020
- Enrollment
- 100 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.